|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We recently established that HRH1 is up-regulated in basal and human epidermal growth factor receptor 2 (HER2)-enriched human breast tumors and that its expression correlates with a worse prognosis.
|
29548821 |
2018 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Phage capable of binding mammalian cells expressing the growth factor receptor ErbB2 and undergoing receptor-mediated endocytosis were isolated by selection of a phage antibody library on breast tumor cells and recovery of infectious phage from within the cell.
|
10329137 |
1999 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Carbonate apatite nanoparticles carry siRNA(s) targeting growth factor receptor genes egfr1 and erbb2 to regress mouse breast tumor.
|
29119846 |
2017 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression.
|
23720052 |
2013 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We studied the concordance of Her-2/neu and topoisomerase IIalpha amplification in primary breast tumors and their metastases by immunostaining and DNA in situ hybridization.
|
11454672 |
2001 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Eleven (0.4%) cases of primary breast tumors with reported HER2 GH were identified over 76 months.
|
30892594 |
2019 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Mice with reduced p27 gene dosage alone do not develop mammary carcinomas but do display substantially shorter tumor latency upon overexpression of erbB2, consistent with a role for p27 as a mammary tumor suppressor gene.
|
15082918 |
2004 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections.
|
17374991 |
2007 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
This NMP is expressed in breast tumor tissues and cell lines along with c-erbB-2, but is not found in corresponding normal tissues.
|
9188464 |
1997 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
To improve insights into the presence among AR expression, immune cell infiltration and HER2, we analysed HER2-positive breast tumours.
|
30208359 |
2018 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
This study confirms that discordance in ER and PR receptor expression between the primary breast tumor and the corresponding metastatic lesions is high, whereas HER2 status remains relatively constant.
|
23723333 |
2013 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Interestingly, we found a positive correlation between FOXM1 expression and HER2 status, pointing to a potential role of FOXM1 as a new drug target in HER2 resistant breast tumour, as FOXM1 inhibitors for cancer treatment were described recently.
|
18254960 |
2008 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We examined the association of recurrence with INT2 and ERBB2 amplification and ERBB2 expression by comparing primary breast tumors from patients surviving without recurrence for > or = 8.5 years after diagnosis, the LTS group, to tumors from patients recurring within two years, the RR group.
|
8750529 |
1996 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Postoperative pathology showed invasive ductal carcinoma involving 4 of 12 surgically excised axillary lymph nodes with HER2 IHC (1+) and FISH negative (HER2 gene not amplified) in the residual tumor of the breast specimen.
|
29052527 |
2017 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Only 25% of patients with HER-2/neu-positive metastatic breast tumors respond favorably to trastuzamab (Herceptin) treatment.
|
11481385 |
2001 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
When targeted by anti-HER2 immunoliposomes encapsulating quenched nitroxides, Hc7 cells, which are novel HER2-overexpressing cells derived from the MCF7 breast tumor cell line, endocytose the liposomes copiously, in contrast to the parent MCF7 cells or control CV1 cells, which do not express HER2.
|
20066490 |
2010 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors.
|
22883974 |
2012 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Here we describe a HER2 FISH methodology to evaluate HER2 gene status in FFPE breast tumor specimens.
|
26820945 |
2016 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In contrast this amplicon was absent in ER+ (0/8) and HER2+ (0/15) breast tumors, and in pancreatic ductal adenocarcinomas (0/150).
|
26317899 |
2015 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Human epidermal growth factor receptor HER3 (ErbB3), especially in association with its relative HER2 (ErbB2), is known as a key oncogene in breast tumour biology.
|
30367623 |
2018 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Discordances between the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), expression between primary breast tumors and their subsequent brain metastases (BM) were investigated in breast cancer patients.
|
28975433 |
2018 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012-2035).
|
28863312 |
2017 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In situ hybridisation showed that elevated levels of c-erbB2 mRNA were specific to malignant cells within the breast tumour.
|
2153396 |
1990 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Our goal was to specifically render tumor cells susceptible to natural cytolytic anti-alphaGal antibodies by using a murine alpha1,3galactosyltransferase (malphaGalT) transgene driven by a designed form of HER2/neu promoter (pNeu), the transcription of which is frequently observed to be above basal in breast tumors.
|
15987454 |
2005 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
An interesting association was found between ER/PR (Oestrogen/Progesterone receptor) and HER2/Neu (Human epidermal growth factor receptor-2) positivity with HPV occurrence in breast tumours.
|
27613186 |
2016 |